Q-omics provides the consensus-scored TOMM22P2 profile across patient tissues and cancer cell-line models. TOMM22P2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TOMM22P2 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, TOMM22P2 RNA expression shows 5,536 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TOMM22P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOMM22P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOMM22P2 survival associations across molecular data types. TOMM22P2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOMM22P2 RNA expression–survival associations across cancer types. High TOMM22P2 expression shows unfavorable associations in COAD, BRCA, KIRP, THCA and DLBC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for TOMM22P2 RNA expression.
This table summarizes TOMM22P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TOMM22P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOMM22P2 shows lower tumor expression in KIRC and KICH. The KIRC box plot shows higher TOMM22P2 RNA expression in normal versus tumor tissue (log2 FC = −0.107, t-test p = .003).
This table shows molecular features associated with TOMM22P2 in patient tissues and cancer cell lines. In patient samples, TOMM22P2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
